Literature DB >> 33212009

Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data.

Deron Britt1, Udi Blankstein2, Matthew Lenardis2, Alexandra Millman2, Ethan Grober3, Yonah Krakowsky3.   

Abstract

INTRODUCTION: Platelet-rich plasma (PRP) is an increasingly used unconventional treatment option for erectile dysfunction (ED). The validity of PRP as a potential treatment for ED has been proposed in limited human trials. Furthermore, the costs associated with PRP for ED treatment are not readily promoted to patients. The goal of this review was to determine the efficacy and costs of PRP based on currently available literature and Canadian data.
METHODS: A comprehensive literature review of available PRP studies and current published data pertaining to cost, availability, and provider clinics globally was conducted using the PubMed database. Physicians offering genital PRP in Canada were identified using internet searches and PRP provider directories. Physician qualifications, clinic locations, and cost information were obtained from provider websites and telephone calls to identified clinics.
RESULTS: Availability of PRP injections offered for treating ED is increasing globally. There are currently no peer-reviewed publications to substantiate anecdotal evidence pertaining to the efficacy of PRP as a viable treatment option for ED patients. Our results indicate 19 providers for PRP injections in Canada, costing on average $1777 CAD per injection. No providers were affiliated with academic institutions and providers varied in their area of clinical speciality and training.
CONCLUSIONS: To our knowledge, there is currently no research underway investigating the clinical efficacy of PRP for ED treatment despite its broad availability and significant cost. Patients should be informed of the lack of substantiated efficacy and safety data, as the reliability of PRP treatments requires further evaluation.

Entities:  

Year:  2021        PMID: 33212009      PMCID: PMC8195577          DOI: 10.5489/cuaj.6947

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  41 in total

Review 1.  Platelet-Rich Plasma.

Authors:  Peter I-Kung Wu; Robert Diaz; Joanne Borg-Stein
Journal:  Phys Med Rehabil Clin N Am       Date:  2016-11       Impact factor: 1.784

2.  Long-term therapeutic effect of cell therapy on improvement in erectile function in a rat model with pelvic neurovascular injury.

Authors:  Xin Gu; Hua Shi; Ethan Matz; Liren Zhong; Ting Long; Cara Clouse; Wei Li; Dong Chen; HyunChul Chung; Sean Murphy; James Yoo; Guiting Lin; Tom Lue; Anthony Atala; John Jackson; Yuanyuan Zhang
Journal:  BJU Int       Date:  2019-02-27       Impact factor: 5.588

Review 3.  Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.

Authors:  Faysal A Yafi; Ira D Sharlip; Edgardo F Becher
Journal:  Sex Med Rev       Date:  2017-10-12

4.  The neuroprotective effect of platelet-rich plasma on erectile function in bilateral cavernous nerve injury rat model.

Authors:  Chien-Chih Wu; Yi-No Wu; Hsiu-O Ho; Kuo-Chiang Chen; Ming-Thau Sheu; Han-Sun Chiang
Journal:  J Sex Med       Date:  2012-08-20       Impact factor: 3.802

5.  The effect of vascular endothelial growth factor and brain-derived neurotrophic factor on cavernosal nerve regeneration in a nerve-crush rat model.

Authors:  P-S Hsieh; D J Bochinski; G T Lin; L Nunes; C S Lin; T F Lue
Journal:  BJU Int       Date:  2003-09       Impact factor: 5.588

Review 6.  Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective.

Authors:  Rachita Dhurat; Ms Sukesh
Journal:  J Cutan Aesthet Surg       Date:  2014 Oct-Dec

Review 7.  Recent advances in the understanding and management of erectile dysfunction.

Authors:  Sarah C Krzastek; Justin Bopp; Ryan P Smith; Jason R Kovac
Journal:  F1000Res       Date:  2019-01-25

8.  Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil.

Authors:  Amr Abdel Raheem; Philip Kell
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

9.  Evaluation of autologous platelet rich plasma for cardiac surgery: outcome analysis of 2000 patients.

Authors:  Amit N Patel; Craig H Selzman; Ganesh S Kumpati; Stephen H McKellar; David A Bull
Journal:  J Cardiothorac Surg       Date:  2016-04-12       Impact factor: 1.637

10.  Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions.

Authors:  Ethan L Matz; Amy M Pearlman; Ryan P Terlecki
Journal:  Investig Clin Urol       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.